Patents Examined by Michael S. Tuscan
-
Patent number: 5525508Abstract: A substantially purified antigen derived from a first species of parasitic nematodes, which antigen is capable of providing protection to a host from parasitism by a second nematode species, which may be the same as or different from the first nematode species, following vaccination of the host with the antigen, characterized in that the antigen is proteinaceous, has a pI between 3.8 and 4.4, can be bound by lentil lectin and Helix promatia lectin and has a molecular weight of approximately 45 kD as determined by SDS-PAGE.Type: GrantFiled: October 6, 1992Date of Patent: June 11, 1996Assignees: Biotech Australia Pty Limited, Commonwealth and Industrial Research OrganizationInventors: Phillip J. Sharp, Barry M. Wagland, Gary S. Cobon
-
Patent number: 5503829Abstract: A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.Type: GrantFiled: November 7, 1994Date of Patent: April 2, 1996Assignee: Institut PasteurInventors: Daniel Ladant, Claude Leclerc, Peter Sebo, Agnes Ullmann
-
Patent number: 5494807Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.Type: GrantFiled: August 12, 1993Date of Patent: February 27, 1996Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe F. Audonnet, Russell R. Gettig
-
Patent number: 5476658Abstract: The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition comprising the simian hepatitis A viral isolate AGM-27; a method of preventing hepatitis A in an animal; and a vaccine comprising the simian hepatitis A viral isolate AGM-27.Type: GrantFiled: March 26, 1991Date of Patent: December 19, 1995Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Sergie A. Tsarev, Suzanne U. Emerson, Michael S. Balayan, Robert H. Purcell
-
Patent number: 5470572Abstract: A cell line capable of producing SIV viral materials without producing infectious viral particles is disclosed. The SIV viral particles produced are immunogenic and non-infectious. The cell line and the products produced by the cell line are useful for diagnostic purposes and for immunization purposes.Type: GrantFiled: July 16, 1993Date of Patent: November 28, 1995Assignee: University of Puerto RicoInventor: Edmundo Kraiselburd
-
Patent number: 5428145Abstract: Non-A, non-B hepatitis (NANB hepatitis) virus RNA and its corresponding polypeptide, related antigen, antibody, and detection systems for detecting NANB hepatitis antigen or antibodies.Type: GrantFiled: August 7, 1992Date of Patent: June 27, 1995Assignee: Immuno Japan, Inc.Inventors: Hiroaki Okamoto, Tetsuo Nakamura
-
Patent number: 5422110Abstract: New immunological carrier systems, DNA encoding the same, and the use of these systems, are disclosed. The carrier systems include chimeric proteins which comprise a leukotoxin polypeptide fused to a selected antigen. The leukotoxin functions to increase the immunogenicity of the antigen fused thereto.Type: GrantFiled: October 14, 1992Date of Patent: June 6, 1995Assignee: University of SaskatchewanInventors: Andrew A. Potter, Mark J. Redmond, Huw P. A. Hughes
-
Patent number: 5405758Abstract: The present invention is directed to a recombinant mite allergen obtainable by expression of a mite-body-derived gene, a gene which codes for said allergen, a mite allergen fragment, a polypeptide having an epitope contained in said allergen, an expression vector capable of expressing the gene, a bacterium, yeast or mammalian cell transformed with said expression vector, a method for producing said allergen, and a pharmaceutical composition or a diagnostic reagent for the treatment of mite allergic diseases.Type: GrantFiled: December 15, 1993Date of Patent: April 11, 1995Assignees: Fumakilla Limited, Hiroshima UniversityInventors: Satoru Oka, Kazuhisa Ono, Seiko Shigeta, Takeshi Wada
-
Patent number: 5389540Abstract: Expression of tetanus toxin fragment C is accomplished employing a DNA coding sequence having a (G+C)-content that has been increased in the region from nucleotide 410 to the 3' end of the coding sequence relative to the wild-type DNA sequence. This allows the production of complete mRNA transcripts. Typically the (G+C)-content is increased in the following regions: (i) nucleotides 510-710, (ii) nucleotides 650-850, (iii) nucleotides 800-1100, (iv) nucleotides 900-1200 and (v) nucleotides 1100 to the 3' end of the coding sequence. The (G+C)-content may also be increased in the region of nucleotides 410-610. These regions in the wild-type DNA encompass terminator sequences.Type: GrantFiled: November 27, 1990Date of Patent: February 14, 1995Assignee: Evans Medical LimitedInventors: Andrew J. Makoff, Michael A. Romanos, Jeffrey J. Clare, Neil F. Fairweather
-
Patent number: 5364773Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.Type: GrantFiled: March 24, 1993Date of Patent: November 15, 1994Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Marion E. Perkus
-
Patent number: 5352596Abstract: An attenuated pseudorabies virus (PRV) having a reduced ability to reactivate from latency is produced by introducing (1) a genomic modification in the early protein 0 (EP0) gene whereby said virus is characterized by the inability to express the early protein 0; or (2) a genomic modification in the large latency transcript (LLT) gene whereby said virus is characterized by disruption of the synthesis of said large latency transcript; or (3) the genomic modifications described in both (1) and (2). The attenuated virus is useful in a vaccine for psuedorabies-susceptible animals, particularly swine. Swine vaccinated with a deletion mutant in the EP0/LLT overlap region displayed reduced virus shedding and fewer clinical signs than animals inoculated with a wild type virus. The deletion mutant-vaccinated swine also harbored less PRV DNA in the nervous tissue and showed reduced ability to reactivate the virus.Type: GrantFiled: September 11, 1992Date of Patent: October 4, 1994Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Andrew K. Cheung, Ronald D. Wesley